Evidence map›Paper›PMID 42683473›Full record

ArticleTurkish journal of chemistry2026

Chitosan microparticle-based antibacterial nasal barrier formulation and in vivo evaluations.

Güliz Ak, Ayça Erek, Tuğba Karakayali, Şadiye Çetin, Şenay Şanlier

Abstract read
In one paragraph

Article in Turkish journal of chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Güliz AkDepartment of Biochemistry, Faculty of Science, Ege University, İzmir, Turkiye.ORCID https://orcid.org/0000-0001-9613-6348
Ayça ErekDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Trakya University, Edirne, Turkiye.ORCID https://orcid.org/0000-0003-3029-9560
Tuğba KarakayaliDepartment of Biochemistry, Graduate School of Natural and Applied Sciences, Ege University, İzmir, Turkiye.ORCID https://orcid.org/0000-0002-1044-5535
Şadiye ÇetinSantek Medical Products, Consultant, Software, Hardware, and Computer Services Industry and Trade Ltd. Co., İzmir, Turkiye.ORCID https://orcid.org/0009-0001-2412-0950
Şenay ŞanlierDepartment of Biochemistry, Faculty of Science, Ege University, İzmir, Turkiye.ORCID https://orcid.org/0000-0001-6532-7221

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microorganisms remain a major cause of infectious diseases, emphasizing the need for alternative and complementary antimicrobial strategies. In this context, plant-derived materials have attracted increasing attention for their antimicrobial and protective properties. Chitosan, a biocompatible and cationic biopolymer, has emerged as an effective carrier system for encapsulating such plant-derived components. In this study, chitosan microparticles were prepared through ionic gelation followed by spray drying and loaded with thyme oil and olive leaf extract. The resulting microparticles exhibited an average size of approximately 1.8 μm and a total phenolic content of 23 mg GAE/g. These microparticles were incorporated into a glycerin-starch ointment to develop a nasal barrier formulation. The formulation showed physicochemical properties compatible with intranasal administration, with pH values in the range of 5-7. The antibacterial activity of the formulation was tested in vivo using BALB/c mice, in which a time-dependent reduction in microbial viability was observed after intranasal administration. Overall, these results suggest that chitosan-based microparticle systems containing plant-derived components could serve as nasal barrier formulations with supportive antibacterial effects.

Indexed as

antibacterial activityChitosan microparticlesnasal barrier formulationolive leaf extractspray dryingthyme oil

Identifiers

PMID42683473
PMCPMC13533061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.